Search research articles
Contact Us
Filters
Showing results (131-140 of 161) with videos related to
Page
of 17
Sort By:
Cancer
|
June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 18, 2023
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer
Sarah Halford, Gareth J Veal, Stephen R Wedge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Nature Communications
|
May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
Rebecca J Lee, Dominic G Rothwell, Nigel Smith, et al.
The Lancet. Oncology
|
May 19, 2015
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R Migden, Alexander Guminski, Ralf Gutzmer, et al.
Journal of the American Academy of Dermatology
|
April 13, 2016
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
British Journal of Cancer
|
August 4, 2020
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
Rebecca Kristeleit, Jeffry Evans, L Rhoda Molife, et al.
The Lancet. Oncology
|
February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S de Bono, Nicole Concin, David S Hong, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 161) with videos related to
Sort By:
Page
of 17
Cancer
|
June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 18, 2023
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer
Sarah Halford, Gareth J Veal, Stephen R Wedge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Nature Communications
|
May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
Rebecca J Lee, Dominic G Rothwell, Nigel Smith, et al.
The Lancet. Oncology
|
May 19, 2015
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R Migden, Alexander Guminski, Ralf Gutzmer, et al.
Journal of the American Academy of Dermatology
|
April 13, 2016
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
British Journal of Cancer
|
August 4, 2020
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
Rebecca Kristeleit, Jeffry Evans, L Rhoda Molife, et al.
The Lancet. Oncology
|
February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S de Bono, Nicole Concin, David S Hong, et al.
Page
of 17